×
Supernus Pharmaceuticals EBIT 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Supernus Pharmaceuticals ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Supernus Pharmaceuticals EBIT 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Supernus Pharmaceuticals ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$24.9B
Dr Reddy's Laboratories (RDY)
$12.6B
BridgeBio Pharma (BBIO)
$6.8B
Bausch Health Cos (BHC)
$2.8B
Amphastar Pharmaceuticals (AMPH)
$1.7B
Personalis (PSNL)
$396M
Taysha Gene Therapies (TSHA)
$314M
Assembly Biosciences (ASMB)
$95M
Sol-Gel Technologies (SLGL)
$25M
Evoke Pharma (EVOK)
$6M
Teligent (TLGT)
$0M